Buy & Sell Deckers Outdoor Corp (DECK) – Deckers Outdoor Corp Price Today
Aura AI Summary
Key Stats
- $13.33BMarket Cap
- Consumer CyclicalSector
- -22.53%3M Drawdown
- $11.59BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 72 daysTypical Hold Time
Deckers Outdoor Corp (DECK) is currently valued at a market capitalization of $13.33B, with an enterprise value of $11.59B. Over the past 52 weeks, Deckers Outdoor Corp has traded between a low of $79.54 and a high of $128.84, highlighting its annual price range. Over the past three months, Deckers Outdoor Corp has recorded a drawdown of -22.53%, reflecting recent price volatility. On average, investors hold Deckers Outdoor Corp for approximately 72 days, indicating typical investor behavior on the platform.
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Most Recent News
SAPHNELO shows strong sales growth and market potential for lupus treatment through 2034.
SAPHNELO (Anifrolumab), a monoclonal antibody for moderate-to-severe systemic lupus erythematosus (SLE), demonstrates robust clinical efficacy by targeting type I interferon receptors. Approved in over 70 countries, it generated $483 million in sales...
California proposes tax on digital software downloads to equalize online and in-store sales tax.
California Governor Gavin Newsom proposed a new tax extending state sales tax to digital prewritten software purchases, aiming to level the playing field between online and physical store sales. The tax, set to take effect January 1, 2027 pending leg...
OCREVUS sales grow 9% in 2025, driven by broad MS treatment and new subcutaneous form
OCREVUS, a treatment for multiple sclerosis (MS), showed strong sales growth of 9% in 2025, reaching about $7.6 billion globally. Its broad efficacy in treating both relapsing and progressive MS, along with the recent approval of a convenient subcuta...
